Adaptimmune Therapeutics plc has announced management changes effective September 2025. Gavin Wood, the Chief Financial Officer, will have his employment terminated on September 9, 2025, due to redundancy. Similarly, John Lunger, the Chief Patient Supply Officer, will leave the company on August 31, 2025, also due to redundancy. Both executives have agreements in place regarding the continuation and exercise of their share options.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptimmune Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001558370-25-011820), on August 29, 2025, and is solely responsible for the information contained therein.